{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-21-142198","form_type":"8-K","ticker":"BDTX","cik":"0001701541","company_name":"Black Diamond Therapeutics, Inc.","filed_at":"2021-11-22T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.736566+00:00","generated_at":"2026-06-28T06:09:32.746644+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Black Diamond Therapeutics CFO Thomas Leggett resigns; Fang Ni named interim CFO","bullets":["CFO Thomas Leggett resigned effective Nov 16, 2021, not due to any disagreement; will stay until Dec 3 for transition.","Board appointed Fang Ni, Pharm.D., Chief Business Officer, as Interim CFO and principal financial officer effective Nov 19.","Erika Jones, VP Finance and Corporate Controller, appointed principal accounting officer effective same date.","Ni's base salary $388,100, eligible for up to 40% annual bonus; severance includes lump sum equal to base salary.","Resignation and appointments are part of planned succession; no family relationships or conflicts reported."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-21-142198","json":"https://secwatch.observer/filing/0001104659-21-142198.json","markdown":"https://secwatch.observer/filing/0001104659-21-142198.md","text":"https://secwatch.observer/filing/0001104659-21-142198.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701541/000110465921142198/0001104659-21-142198-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701541/000110465921142198/tm2133581d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T06:09:32.746644+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1fe3328a1c","claim":"Thomas Leggett resigned as Chief Financial Officer at Black Diamond Therapeutics, Inc..","evidence_excerpt":"On November 16, 2021, Thomas Leggett resigned from his position as Chief Financial Officer (principal financial and accounting officer) of Black Diamond Therapeutics, Inc. (the “ Company ”) effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1701541/000110465921142198/0001104659-21-142198-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"61d2357105","claim":"Erika Jones was appointed as principal accounting officer at Black Diamond Therapeutics, Inc..","evidence_excerpt":"Effective November 19, 2021, the Board appointed Erika Jones, the Company’s Vice President, Finance and Corporate Controller, as principal accounting officer until a successor is appointed.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1701541/000110465921142198/0001104659-21-142198-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"principal accounting officer"}],"fact_type":"executive_change"},{"claim_id":"b7edd7b58a","claim":"Fang Ni was appointed as Interim Chief Financial Officer at Black Diamond Therapeutics, Inc..","evidence_excerpt":"Effective November 19, 2021, the Board of Directors of the Company (the “ Board ”) appointed Fang Ni, Pharm. D., the Company’s Chief Business Officer, as Interim Chief Financial Officer and principal financial officer until a successor is appointed.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1701541/000110465921142198/0001104659-21-142198-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}